Rugang Zhang
Department of Experimental Therapeutics, Division of Cancer Medicine
About Rugang Zhang
Dr. Zhang received his Ph.D. in Cell Biology from the Institute of Biochemistry and Cell Biology, Shanghai Institutes of Biological Sciences, Chinese Academy of Science. His postdoctoral training came from the Institute for Cancer Research, Fox Chase Cancer Center, where he later became an Assistant Professor. He joined The Wistar Institute as an Associate Professor in 2012, was promoted to Professor in 2015 and later became holder of the Christopher M. Davis Endowed Professor & Leader, Immunology, Microenvironment and Metastasis Program. He assumed various leadership roles during his time at Wistar and was appointed Deputy Director in 2017. He joined The University of Texas MD Anderson Cancer Center as a Professor and Chair of Department of Experimental Therapeutics in 2023.
Dr. Zhang is committed to finding a cure for epithelial ovarian cancer, the most lethal gynecological malignancy in the developed world. In addition, he investigates the aging process of normal mammalian cells and its role in both tissue aging and cancer development for the discovery of therapeutic applications.
Present Title & Affiliation
Primary Appointment
The John M. O'Quinn Endowed Chair in Cancer Research, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Department Chair, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Faculty, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX
Program Co-Leader, CCSG Developmental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Faculty, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX
Research Interests
The Zhang laboratory studies ovarian cancer biology with the goal of developing novel therapeutic approaches to combat the disease with precision. In particular, the lab investigates how alterations in epigenetics— or the heritable changes that affects gene expression without alterations in the underlying DNA sequence—contribute to epithelial ovarian cancer. The ultimate goal of this line of investigation is to leverage these newly gained mechanistic insights for developing new therapeutics in a personalized manner based on one’s unique genetic and/or pathway signatures.
The Zhang laboratory also investigates the mechanisms that underlie aging in normal mammalian cells and how this process is implicated in tissue aging or evaded by tumor cells during malignant transformation. In particular, the lab focuses on epigenetic and metabolic pathways that regulate the aging process. The overarching goal for identifying such mechanisms is the development of novel strategies to promote healthy aging and combat cancer.
EPIGENETICS OF EPITHELIAL OVARIAN CANCER
A major discovery in recent cancer genome-wide sequencing is the identification of significant genetic changes in chromatin-modifying genes. However, despite great strides in identifying the various epigenetic enzymes/factors involved in cancer, the translational application of these findings in cancer intervention remains to be explored. The Zhang lab will pursue these issues in the coming years by focusing on the epigenetic SWItch/Sucrose Non-Fermentable (SWI/SNF) and PP2A complexes as proof of principles in the context of ovarian cancer.
a)Mechanism-guided therapeutic strategies for genetic alterations that affect the SWI/SNF chromatin remodeling complex in epithelial ovarian cancer (such as ARID1A mutation in clear cell and endometrioid subtypes of ovarian cancer, and CARM1 amplification/overexpression in high-grade serous ovarian cancer).
b)Epigenetic approaches to chemotherapy resistance and cancer stemness in epithelial ovarian cancer.
c)Epigenetic approaches to primer for and/or synergize with immunological therapy in epithelial ovarian cancer.
d)PARP inhibitors resistance mechanism and approaches to sensitizing BRCA-proficient ovarian cancer to PARP inhibitors.
e) Epigenetic and immunological approaches to mutations in subunits of the PP2A complex (e.g., PPP2R1A) in ovarian and endometrial cancers.
EPIGENETIC AND METABOLIC BASIS OF CELLULAR SENESCENCE
Cellular senescence is a state of stable cell growth arrest that is accompanied by drastic molecular and phenotypic changes. Cellular senescence is a major contributor to tissue aging and plays a context-dependent role in tumor development. For example, cellular senescence is tumor suppressive and overcoming the senescence-associated cell growth arrest is a necessary step during cell transformation. In contrast to its tumor suppressive function, senescent cells can also promote cancer by acquiring a secretory phenotype and create a pro-tumorigenic microenvironment. The biological process of cellular senescence represents an ideal paradigm to examine the role of the DNA damage response, epigenetically determined chromatin structure, and metabolic reprogramming during tissue aging and cancer development.
a)Chromatin basis of the senescence-associated secretory phenotype.
b)Targeting senescence-associated metabolic vulnerability to develop cancer therapeutics.
c)Targeting senescence-associated immunological vulnerability to develop cancer therapeutics.
Education & Training
Degree-Granting Education
| 2002 | Chinese Academy of Sciences, Institute of Biochemistry and Cell Biology, Shanghai, CN, Ph.D. in Molecular and Cellular Biology |
| 1997 | Anhui Normal University, Anhui, CN, BS in Biology |
Postgraduate Training
| 2003-2008 | Postdoctoral Associate, Fox Chase Cancer Center, Philadelphia, Pennsylvania |
| 2002-2003 | Postdoctoral Fellow, University of Pennsylvania, Philadelphia, Pennsylvania |
Experience & Service
Academic Appointments
Christopher M. Davis Endowed Professor, The Wistar Institute, Philadelphia, PA, 2021 - 2023
Professor, The Wistar Institute, Philadelphia, PA, 2015 - 2023
Associate Professor, The Wistar Institute, Philadelphia, PA, 2012 - 2015
Adjunct Professor, Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2012 - 2023
Assistant Professor, Fox Chase Cancer Center, Philadelphia, PA, 2008 - 2012
Postdoctoral Associate, Fox Chase Cancer Center, Philadelphia, PA, 2003 - 2008
Postdoctoral Fellow, University of Pennsylvania, Philadelphia, PA, 2002 - 2003
Administrative Appointments/Responsibilities
Department Chair, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
Program Co-Leader, CCSG Developmental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
Program Leader, Department of Immunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA, 2020 - 2023
Deputy Director, NCI-Designated Wistar Institute Cancer Center, Philadelphia, PA, 2017 - 2023
Program Co-Leader, Department of Gene Expression & Regulation Program, The Wistar Institute, Philadelphia, PA, 2016 - 2020
Chair of Education Program, Fox Chase Cancer Center, Philadelphia, PA, 2010 - 2012
Other Appointments/Responsibilities
External Advisor Board, Wistar Institute’s P01: Targeting p53 mutation in ovarian cancers, Philadelphia, PA, 2023 - Present
Member of Faculty Recruitment Panel (FRP), The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
External Advisor Board, Dana-Farber Cancer Institute’s P01: Targeting replication stress and DNA damage response in uterine cancers, Boston, MA, 2023 - Present
Member of Department Chair Search Committee for EMC and MCO, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
Vice Chair, Community of Science Chairs, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
External Advisory Board Member, Center for Chromatin NanoImaging in Cancer External Advisory Panel, Chicago, IL, 2023 - Present
External Advisory Board, NIH U54 Cellular Cancer Biology Imaging Research Center, Northwestern University, Chicago, IL, 2022 - Present
External Examiner of Faculty Promotion Committee, University of Virginia, Charlottesville, VA, 2021 - Present
External Examiner of Faculty Promotion Committee, Fox Chase Cancer Center, Philadelphia, PA, 2021 - Present
External Examiner of Faculty Promotion Committee, Ohio State University, Columbus, OH, 2021 - Present
External Advisory Board, Dana-Farber Cancer Institute's P01: Targeting replication stress and DNA damage response in uterine cancers, Boston, MA, 2021 - Present
Chair of Search Committee for IMM Co-Program Leader, The Wistar Institute, Philadelphia, PA, 2021 - Present
External Examiner of Faculty Promotion Committee, University of Miami, Miami, FL, 2021 - Present
Translational Steering Committee-Executive Committee, The Wistar Institute/Helen F. Graham Cancer Center and Research Institute, Christiana Care, Philadelphia, PA, 2020 - Present
Co-Chair of Faculty Search Committee (IMM/VIC), The Wistar Institute, Philadelphia, PA, 2020 - Present
External Examiner of Faculty Promotion Committee, Weill Cornell Medicine, New York, NY, 2020 - Present
External Examiner of Faculty Appointment Committee, University of Chicago, Chicago, IL, 2020 - Present
External Examiner of Faculty Promotion Committee, University of Pittsburgh, Pittsburgh, PA, 2020 - Present
Member of Faculty Search Committee (IMM), The Wistar Institute, Philadelphia, PA, 2019 - Present
External Examiner of Faculty Promotion Committee, Rutgers University, Neward, NJ, 2019 - Present
Basser Center Strategic Planning Advisory Committee, University of Pennsylvania, Philadelphia, PA, 2019 - Present
External Examiner of Faculty Promotion Committee, University of North Carolina, Chapel Hill, NC, 2019 - Present
Member of Faculty Search Committee (GER), The Wistar Institute, Philadelphia, PA, 2019 - Present
External Examiner of Faculty Promotion Committee, University of Connecticut, Storrs, CT, 2019 - Present
External Examiner of Faculty Promotion Committee, University of California, Davis, Davis, CA, 2018 - Present
External Examiner of Faculty Promotion Committee, University of Minnesota, Minneapolis, MN, 2018 - Present
External Examiner of Faculty Promotion Committee, University of Kentucky, Lexington, KY, 2018 - Present
External Examiner of Faculty Promotion Committee, University of North Carolina, Chapel Hill, Chapel Hill, NC, 2018 - Present
External Examiner of Faculty Promotion Committee, Fox Chase Cancer Center, Philadelphia, PA, 2018 - Present
Member of Executive Committee of Wistar Cancer Center, The Wistar Institute, Philadelphia, PA, 2017 - 2023
Member of Internal Mock Study Section, The Wistar Institute, Philadelphia, PA, 2017 - 2023
External Examiner of Faculty Promotion Committee, Ohio State University, Columbus, OH, 2017 - Present
External Examiner of Faculty Promotion Committee, Emory University, Atlanta, GA, 2017 - Present
External Examiner of Faculty Promotion Committee, University of Pennsylvania, Philadelphia, PA, 2017 - Present
External Examiner of Faculty Promotion Committee, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 2017 - Present
Member of Faculty Search Committee (MCO), The Wistar Institute, Philadelphia, PA, 2016 - Present
External Examiner of Faculty Promotion Committee, University of Minnesota, Minneapolis, MN, 2016 - Present
External Examiner of Faculty Promotion Committee, University of Kansas, Lawrence, KS, 2016 - Present
Member of Leadership Council, The Wistar Institute, Philadelphia, PA, 2016 - 2023
Member of Faculty Search Committee (GER), The Wistar Institute, Philadelphia, PA, 2016 - Present
Chair of Faculty Search Committee (Ovarian Cancer), The Wistar Institute, Philadelphia, PA, 2016 - Present
Member of Faculty Search Committee (GER), The Wistar Institute, Philadelphia, PA, 2015 - Present
Member of Faculty Search Committee (MCO), The Wistar Institute, Philadelphia, PA, 2015 - Present
External Examiner of Faculty Promotion Committee, Indiana University, Bloomington, IN, 2015 - Present
Member of Student Advisory Committee, Cancer Biology Graduate Program, University of Pennsylvania School of Medicine, Philadelphia, PA, 2014 - 2017
Member of Junior Faculty Mentoring Committee, The Wistar Institute, Philadelphia, PA, 2014 - 2023
Member of Faculty Search Committee (GER), The Wistar Institute, Philadelphia, PA, 2014 - Present
Ad hoc Member of Faculty Promotion Committee, The Scripps Research Institute, La Jolla, CA, 2014 - Present
Member of Faculty Search Committee (Functional Genomics), The Wistar Institute, Philadelphia, PA, 2013 - Present
Member of Faculty Council, The Wistar Institute, Philadelphia, PA, 2013 - 2023
Member, Cell & Molecular Biology Graduate Group, University of Pennsylvania, Philadelphia, PA, 2013 - 2023
Member of Faculty Search Committee (GER), The Wistar Institute, Philadelphia, PA, 2012 - Present
Member of Committee on Appointment and Promotion, The Wistar Institute, Philadelphia, PA, 2012 - 2023
Member of Committee on Experimental Medicine, Gynecological Oncology Group, Philadelphia, PA, 2010 - 2018
Institutional Committee Activities
Member, Joint Search Committee for Chair, Department of Epigenetics and Molecular Carcinogenesis and Chair, Department of Molecular and Cellular Oncology, 2023 - Present
Member, Faculty Recruitment Panel, 2023 - Present
Honors & Awards
| 2021 | Christopher M. Davis Endowed Chair Professor, Wistar Institute |
| 2016 | Inaugural Liz Tilberis Prize for Excellence in Ovarian Cancer Research, Ovarian Cancer Research Fund Alliance/National Ovarian Cancer Conference |
| 2011 | Highlighted Project, Congressional Directed Medical Research Program Annual Report |
| 2010 | DoD Ovarian Cancer Academy Award, Department of Defense |
| 2009 | FCCC/UPENN Ovarian Cancer SPORE Career Development Award, Fox Chase Cancer Center |
| 2008 | Liz Tilberis Scholar, Ovarian Cancer Research Fund |
| 2004 | Glenn/AFAR Postdoctoral Fellowship Award, American Federation for Aging Research |
| 2004 | W. J. Avery Postdoctoral Fellowship, Fox Chase Cancer Center |
| 2001 | DI-AO Award, Chinese Academy of Sciences |
| 2001 | International Meeting Travel Award, Shanghai-Unilever R&D Fund |
| 2000 | DI-AO Prize, Chinese Academy of Sciences |
| 1999 | WEI-HUA Prize, Chinese Academy of Sciences |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Nie, H, Saini, P, Miyamoto, T, Liao, L, Zielinski, RJ, Liu, H, Zhou, W, Wang, C, Murphy, B, Towers, M, Yang, T, Qi, Y, Kannan, T, Kossenkov, AV, Tateno, H, Claiborne, DT, Zhang, N, Abdel-Mohsen, M, Zhang, R. Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38565883.
- Wang, C, Tanizawa, H, Hill, C, Havas, A, Zhang, Q, Liao, L, Hao, X, Lei, X, Wang, L, Nie, H, Qi, Y, Tian, B, Gardini, A, Kossenkov, AV, Goldman, AR, Berger, SL, Noma, KI, Adams, PD, Zhang, R. METTL3-mediated chromatin contacts promote stress granule phase separation through metabolic reprogramming during senescence. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38926365.
- Hao, X, Zhao, B, Towers, M, Liao, L, Monteiro, EL, Xu, X, Freeman, C, Peng, H, Tang, HY, Havas, A, Kossenkov, AV, Berger, SL, Adams, PD, Speicher, DW, Schultz, D, Marmorstein, R, Zaret, KS, Zhang, R. TXNRD1 drives the innate immune response in senescent cells with implications for age-associated inflammation. Nature Aging 4(2):185-197, 2024. e-Pub 2024. PMID: 38267705.
- Bordoloi D, Kulkarni AJ, Adeniji OS, Pampena MB, Bhojnagarwala PS, Zhao S, Ionescu C, Perales-Puchalt A, Parzych EM, Zhu X, Ali AR, Cassel J, Zhang R, Betts MR, Abdel-Mohsen M, Weiner DB. Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers. Sci Adv 9(44):eadh4379, 2023. e-Pub 2023. PMID: 37910620.
- Lombardi S, Goldman AR, Tang HY, Kossenkov AV, Liu H, Zhou W, Herlyn M, Lin J, Zhang R. Targeting Fatty Acid Reprogramming Suppresses CARM1-expressing Ovarian Cancer. Cancer Res Commun 3(6):1067-1077, 2023. e-Pub 2023. PMID: 37377614.
- Zhou W, Liu H, Yuan Z, Zundell J, Towers M, Lin J, Lombardi S, Nie H, Murphy B, Yang T, Wang C, Liao L, Goldman AR, Kannan T, Kossenkov AV, Drapkin R, Montaner LJ, Claiborne DT, Zhang N, Wu S, Zhang R. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer Cell 41(4):740-756, 2023. e-Pub 2023. PMID: 36963401.
- Elbasir A, Ye Y, Schäffer DE, Hao X, Wickramasinghe J, Tsingas K, Lieberman PM, Long Q, Morris Q, Zhang R, Schäffer AA, Auslander N. A deep learning approach reveals unexplored landscape of viral expression in cancer. Nat Commun 14(1):785, 2023. e-Pub 2023. PMID: 36774364.
- Atiya HI, Frisbie L, Goldfeld E, Orellana T, Donnellan N, Modugno F, Calderon M, Watkins S, Zhang R, Elishaev E, Soong TR, Vlad A, Coffman L. Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation. Cancer Res 82(24):4680-4693, 2022. e-Pub 2022. PMID: 36219681.
- Bordoloi D, Bhojnagarwala PS, Perales-Puchalt A, Kulkarni AJ, Zhu X, Liaw K, O'Connell RP, Park DH, Kulp DW, Zhang R, Weiner DB. A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy. JCI Insight 7(22), 2022. e-Pub 2022. PMID: 36509287.
- Liu H, Lin J, Zhou W, Moses R, Dai Z, Kossenkov AV, Drapkin R, Bitler BG, Karakashev S, Zhang R. KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. Cancer Immunol Res 10(8):1028-1038, 2022. e-Pub 2022. PMID: 35726891.
- Hao X, Shiromoto Y, Sakurai M, Towers M, Zhang Q, Wu S, Havas A, Wang L, Berger S, Adams PD, Tian B, Nishikura K, Kossenkov AV, Liu P, Zhang R. ADAR1 downregulation by autophagy drives senescence independently of RNA editing by enhancing p16INK4a levels. Nat Cell Biol 24(8):1202-1210, 2022. e-Pub 2022. PMID: 35851616.
- Lin J, Guo D, Liu H, Zhou W, Wang C, Müller I, Kossenkov AV, Drapkin R, Bitler BG, Helin K, Zhang R. The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity. Cancer Immunol Res 9(12):1413-1424, 2021. e-Pub 2021. PMID: 34848497.
- Zundell JA, Fukumoto T, Lin J, Fatkhudinov N, Nacarelli T, Kossenkov AV, Liu Q, Cassel J, Hu CA, Wu S, Zhang R. Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers. Cancer Res 81(20):5325-5335, 2021. e-Pub 2021. PMID: 34548333.
- Lin J, Liu H, Fukumoto T, Zundell J, Yan Q, Tang CA, Wu S, Zhou W, Guo D, Karakashev S, Hu CA, Sarma K, Kossenkov AV, Zhang R. Targeting the IRE1α/XBP1s pathway suppresses CARM1-expressing ovarian cancer. Nat Commun 12(1):5321, 2021. e-Pub 2021. PMID: 34493732.
- Fukumoto T, Lin J, Fatkhutdinov N, Liu P, Somasundaram R, Herlyn M, Zhang R, Nishigori C. ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. J Invest Dermatol 141(6):1564-1572.e4, 2021. e-Pub 2021. PMID: 33333124.
- Liu P, Li F, Lin J, Fukumoto T, Nacarelli T, Hao X, Kossenkov AV, Simon MC, Zhang R. m6A-independent genome-wide METTL3 and METTL14 redistribution drives the senescence-associated secretory phenotype. Nat Cell Biol 23(4):355-365, 2021. e-Pub 2021. PMID: 33795874.
- Wu S, Fukumoto T, Lin J, Nacarelli T, Wang Y, Ong D, Liu H, Fatkhutdinov N, Zundell JA, Karakashev S, Zhou W, Schwartz LE, Tang HY, Drapkin R, Liu Q, Huntsman DG, Kossenkov AV, Speicher DW, Schug ZT, Van Dang C, Zhang R. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nat Cancer 2(2):189-200, 2021. e-Pub 2021. PMID: 34085048.
- Hao X, Zhao B, Zhou W, Liu H, Fukumoto T, Gabrilovich D, Zhang R. Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype. iScience 24(1):102016, 2021. e-Pub 2021. PMID: 33490922.
- Perego M, Tyurin VA, Tyurina YY, Yellets J, Nacarelli T, Lin C, Nefedova Y, Kossenkov A, Liu Q, Sreedhar S, Pass H, Roth J, Vogl T, Feldser D, Zhang R, Kagan VE, Gabrilovich DI. Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils. Sci Transl Med 12(572), 2020. e-Pub 2020. PMID: 33268511.
- Wu S, Zhang R. CD38-expressing macrophages drive age-related NAD+ decline. Nat Metab 2(11):1186-1187, 2020. e-Pub 2020. PMID: 33199923.
- Hashimoto A, Fukumoto T, Zhang R, Gabrilovich D. Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors. Cancer Immunol Immunother 69(9):1929-1936, 2020. e-Pub 2020. PMID: 32435850.
- Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, Medvedev S, Kinose Y, Devins K, Verma P, Ly K, Wang Y, Greenberg RA, Schwartz L, Johnson N, Scharpf RB, Mills GB, Zhang R, Velculescu VE, Brown EJ, Simpkins F. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun 11(1):3726, 2020. e-Pub 2020. PMID: 32709856.
- Li, J, Wang, W, Zhang, Y, Cieślik, M, Guo, J, Tan, M, Green, M, Wang, W, Lin, H, Li, W, Wei, S, Zhou, J, Li, G, Jing, X, Vatan, L, Zhao, L, Bitler, BG, Zhang, R, Cho, KR, Dou, Y, Kryczek, I, Chan, TA, Huntsman, DG, Chinnaiyan, AM, Zou, W. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. Journal of Clinical Investigation 130(5):2712-2726, 2020. e-Pub 2020. PMID: 32027624.
- Zhao B, Liu P, Fukumoto T, Nacarelli T, Fatkhutdinov N, Wu S, Lin J, Aird KM, Tang HY, Liu Q, Speicher DW, Zhang R. Topoisomerase 1 cleavage complex enables pattern recognition and inflammation during senescence. Nat Commun 11(1):908, 2020. e-Pub 2020. PMID: 32075966.
- Nacarelli T, Fukumoto T, Zundell JA, Fatkhutdinov N, Jean S, Cadungog MG, Borowsky ME, Zhang R. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer. Cancer Res 80(4):890-900, 2020. e-Pub 2020. PMID: 31857293.
- Karakashev S, Fukumoto T, Zhao B, Lin J, Wu S, Fatkhutdinov N, Park PH, Semenova G, Jean S, Cadungog MG, Borowsky ME, Kossenkov AV, Liu Q, Zhang R. EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition. Cancer Cell 37(2):157-167.e6, 2020. e-Pub 2020. PMID: 32004442.
- Yuan, J, Kensler, KH, Hu, Z, Zhang, Y, Zhang, T, Jiang, J, Xu, M, Pan, Y, Long, M, Montone, KT, Tanyi, J, Fan, Y, Zhang, R, Hu, X, Rebbeck, TR, Zhang, L. Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry. PLoS genetics 16(2), 2020. e-Pub 2020. PMID: 32059012.
- Nacarelli T, Zhao B, Hao X, Zhang R. ARID1A mutation and genomic stability. Mol Cell Oncol 7(3):1690923, 2020. e-Pub 2020. PMID: 32391414.
- Karakashev S, Zhang R. Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors. Mol Cell Oncol 7(4):1760675, 2020. e-Pub 2020. PMID: 32944622.
- Iwasaki O, Tanizawa H, Kim KD, Kossenkov A, Nacarelli T, Tashiro S, Majumdar S, Showe LC, Zhang R, Noma KI. Involvement of condensin in cellular senescence through gene regulation and compartmental reorganization. Nat Commun 10(1):5688, 2019. e-Pub 2019. PMID: 31831736.
- Fukumoto T, Fatkhutdinov N, Zundell JA, Tcyganov EN, Nacarelli T, Karakashev S, Wu S, Liu Q, Gabrilovich DI, Zhang R. HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. Cancer Res 79(21):5482-5489, 2019. e-Pub 2019. PMID: 31311810.
- Zhao B, Lin J, Rong L, Wu S, Deng Z, Fatkhutdinov N, Zundell J, Fukumoto T, Liu Q, Kossenkov A, Jean S, Cadungog MG, Borowsky ME, Drapkin R, Lieberman PM, Abate-Shen CT, Zhang R. ARID1A promotes genomic stability through protecting telomere cohesion. Nat Commun 10(1):4067, 2019. e-Pub 2019. PMID: 31492885.
- Nacarelli, T, Zhang, R. NAD+ metabolism controls inflammation during senescence. Molecular and Cellular Oncology 6(4), 2019. e-Pub 2019. PMID: 31211232.
- Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer 125(12):1963-1972, 2019. e-Pub 2019. PMID: 30835824.
- Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, Liu P, Kossenkov AV, Showe LC, Jean S, Zhang L, Zhang R. N6-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance. Cancer Res 79(11):2812-2820, 2019. e-Pub 2019. PMID: 30967398.
- Wu S, Fatkhutdinov N, Rosin L, Luppino JM, Iwasaki O, Tanizawa H, Tang HY, Kossenkov AV, Gardini A, Noma KI, Speicher DW, Joyce EF, Zhang R. ARID1A spatially partitions interphase chromosomes. Sci Adv 5(5):eaaw5294, 2019. e-Pub 2019. PMID: 31131328.
- Nacarelli T, Lau L, Fukumoto T, Zundell J, Fatkhutdinov N, Wu S, Aird KM, Iwasaki O, Kossenkov AV, Schultz D, Noma KI, Baur JA, Schug Z, Tang HY, Speicher DW, David G, Zhang R. NAD+ metabolism governs the proinflammatory senescence-associated secretome. Nat Cell Biol 21(3):397-407, 2019. e-Pub 2019. PMID: 30778219.
- Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, Hu X, Zhang Y, Wang Y, Jiang J, Li C, Zhong X, Montone KT, Guan G, Tanyi JL, Fan Y, Xu X, Morgan MA, Long M, Zhang Y, Zhang R, Sood AK, Rebbeck TR, Dang CV, Zhang L. Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell 34(4):549-560.e9, 2018. e-Pub 2018. PMID: 30300578.
- Wu S, Fatkhutdinov N, Fukumoto T, Bitler BG, Park PH, Kossenkov AV, Trizzino M, Tang HY, Zhang L, Gardini A, Speicher DW, Zhang R. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells. Nat Commun 9(1):4116, 2018. e-Pub 2018. PMID: 30297712.
- Singha B, Harper SL, Goldman AR, Bitler BG, Aird KM, Borowsky ME, Cadungog MG, Liu Q, Zhang R, Jean S, Drapkin R, Speicher DW. CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. Sci Rep 8(1):14725, 2018. e-Pub 2018. PMID: 30282979.
- Barnoud T, Budina-Kolomets A, Basu S, Leu JI, Good M, Kung CP, Liu J, Liu Q, Villanueva J, Zhang R, George DL, Murphy ME. Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78(19):5694-5705, 2018. e-Pub 2018. PMID: 30115697.
- Trizzino M, Barbieri E, Petracovici A, Wu S, Welsh SA, Owens TA, Licciulli S, Zhang R, Gardini A. The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II. Cell Rep 23(13):3933-3945, 2018. e-Pub 2018. PMID: 29949775.
- Fukumoto T, Park PH, Wu S, Fatkhutdinov N, Karakashev S, Nacarelli T, Kossenkov AV, Speicher DW, Jean S, Zhang L, Wang TL, Shih IM, Conejo-Garcia JR, Bitler BG, Zhang R. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22(13):3393-3400, 2018. e-Pub 2018. PMID: 29590609.
- Karakashev S, Zhu H, Wu S, Yokoyama Y, Bitler BG, Park PH, Lee JH, Kossenkov AV, Gaonkar KS, Yan H, Drapkin R, Conejo-Garcia JR, Speicher DW, Ordog T, Zhang R. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nat Commun 9(1):631, 2018. e-Pub 2018. PMID: 29434212.
- Zhao B, Zhang W, Cun Y, Li J, Liu Y, Gao J, Zhu H, Zhou H, Zhang R, Zheng P. Mouse embryonic stem cells have increased capacity for replication fork restart driven by the specific Filia-Floped protein complex. Cell Res 28(1):69-89, 2018. e-Pub 2018. PMID: 29125140.
- Fukumoto T, Zhang R, Bitler BG. Epigenetic inhibitors for the precision treatment of ARID1A-mutant ovarian cancers: what are the next steps?. Expert Rev Precis Med Drug Dev 3(4):233-236, 2018. e-Pub 2018. PMID: 30525111.
- Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Cell Rep 21(12):3398-3405, 2017. e-Pub 2017. PMID: 29262321.
- Bitler BG, Wu S, Park PH, Hai Y, Aird KM, Wang Y, Zhai Y, Kossenkov AV, Vara-Ailor A, Rauscher FJ, Zou W, Speicher DW, Huntsman DG, Conejo-Garcia JR, Cho KR, Christianson DW, Zhang R. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell Biol 19(8):962-973, 2017. e-Pub 2017. PMID: 28737768.
- Kim H, George E, Ragland R, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown E, Simpkins F. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models. Clin Cancer Res 23(12):3097-3108, 2017. e-Pub 2017. PMID: 27993965.
- Stephen TL, Payne KK, Chaurio RA, Allegrezza MJ, Zhu H, Perez-Sanz J, Perales-Puchalt A, Nguyen JM, Vara-Ailor AE, Eruslanov EB, Borowsky ME, Zhang R, Laufer TM, Conejo-Garcia JR. SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. Immunity 46(1):51-64, 2017. e-Pub 2017. PMID: 28099864.
- George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight 2(1):e89760, 2017. e-Pub 2017. PMID: 28097235.
- Svoronos N, Perales-Puchalt A, Allegrezza MJ, Rutkowski MR, Payne KK, Tesone AJ, Nguyen JM, Curiel TJ, Cadungog MG, Singhal S, Eruslanov EB, Zhang P, Tchou J, Zhang R, Conejo-Garcia JR. Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. Cancer Discov 7(1):72-85, 2017. e-Pub 2017. PMID: 27694385.
- Zhu H, Le L, Tang HY, Speicher DW, Zhang R. Detection of the Ubiquitinome in Cells Undergoing Oncogene-Induced Senescence. Methods Mol Biol 1534:127-137, 2017. e-Pub 2017. PMID: 27812874.
- Aird KM, Iwasaki O, Kossenkov AV, Tanizawa H, Fatkhutdinov N, Bitler BG, Le L, Alicea G, Yang TL, Johnson FB, Noma KI, Zhang R. HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci. J Cell Biol 215(3):325-334, 2016. e-Pub 2016. PMID: 27799366.
- Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG, Zhang R. BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Res 76(21):6320-6330, 2016. e-Pub 2016. PMID: 27803105.
- Goldman AR, Bitler BG, Schug Z, Conejo-Garcia JR, Zhang R, Speicher DW. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level. Mol Cell Proteomics 15(11):3348-3360, 2016. e-Pub 2016. PMID: 27654507.
- Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, Yokoyama Y, Kossenkov AV, Bradner JE, Conejo-Garcia JR, Zhang R. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Rep 16(11):2829-2837, 2016. e-Pub 2016. PMID: 27626654.
- Fatkhutdinov N, Sproesser K, Krepler C, Liu Q, Brafford PA, Herlyn M, Aird KM, Zhang R. Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma. Mol Cancer Res 14(9):767-75, 2016. e-Pub 2016. PMID: 27297629.
- Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532(7598):250-4, 2016. e-Pub 2016. PMID: 27042933.
- Bitler BG, Aird KM, Zhang R. Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations. Mol Cell Oncol 3(1):e1032476, 2016. e-Pub 2016. PMID: 27308548.
- Wu S, Zhang R, Bitler BG. Arid1a controls tissue regeneration. Stem Cell Investig 3(AUG):35, 2016. e-Pub 2016. PMID: 27582418.
- Wang Z, Deng Z, Dahmane N, Tsai K, Wang P, Williams DR, Kossenkov AV, Showe LC, Zhang R, Huang Q, Conejo-Garcia JR, Lieberman PM. Telomeric repeat-containing RNA (TERRA) constitutes a nucleoprotein component of extracellular inflammatory exosomes. Proc Natl Acad Sci U S A 112(46):E6293-300, 2015. e-Pub 2015. PMID: 26578789.
- Zhu H, Ren S, Bitler BG, Aird KM, Tu Z, Skordalakes E, Zhu Y, Yan J, Sun Y, Zhang R. SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase. Cell Rep 13(6):1183-1193, 2015. e-Pub 2015. PMID: 26527005.
- Caino MC, Ghosh JC, Chae YC, Vaira V, Rivadeneira DB, Faversani A, Rampini P, Kossenkov AV, Aird KM, Zhang R, Webster MR, Weeraratna AT, Bosari S, Languino LR, Altieri DC. PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proc Natl Acad Sci U S A 112(28):8638-43, 2015. e-Pub 2015. PMID: 26124089.
- Aird KM, Zhang R. ATM in senescence. Oncotarget 6(17):14729-30, 2015. e-Pub 2015. PMID: 26143490.
- Zhao B, Zhang WD, Duan YL, Lu YQ, Cun YX, Li CH, Guo K, Nie WH, Li L, Zhang R, Zheng P. Filia Is an ESC-Specific Regulator of DNA Damage Response and Safeguards Genomic Stability. Cell Stem Cell 16(6):684-98, 2015. e-Pub 2015. PMID: 25936915.
- Aird KM, Worth AJ, Snyder NW, Lee JV, Sivanand S, Liu Q, Blair IA, Wellen KE, Zhang R. ATM couples replication stress and metabolic reprogramming during cellular senescence. Cell Rep 11(6):893-901, 2015. e-Pub 2015. PMID: 25937285.
- Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, IeM S, Conejo-Garcia JR, Speicher DW, Zhang R. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med 21(3):231-8, 2015. e-Pub 2015. PMID: 25686104.
- Rutkowski MR, Stephen TL, Svoronos N, Allegrezza MJ, Tesone AJ, Perales-Puchalt A, Brencicova E, Escovar-Fadul X, Nguyen JM, Cadungog MG, Zhang R, Salatino M, Tchou J, Rabinovich GA, Conejo-Garcia JR. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27(1):27-40, 2015. e-Pub 2015. PMID: 25533336.
- Bengsch F, Tu Z, Tang HY, Zhu H, Speicher DW, Zhang R. Comprehensive analysis of the ubiquitinome during oncogene-induced senescence in human fibroblasts. Cell Cycle 14(10):1540-7, 2015. e-Pub 2015. PMID: 25785348.
- Yokoyama Y, Zhu H, Zhang R, Noma K. A novel role for the condensin II complex in cellular senescence. Cell Cycle 14(13):2160-70, 2015. e-Pub 2015. PMID: 26017022.
- Zeppernick F, Ardighieri L, Hannibal CG, Vang R, Junge J, Kjaer SK, Zhang R, Kurman RJ, IeM S. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. Am J Surg Pathol 38(12):1603-11, 2014. e-Pub 2014. PMID: 25188864.
- Aird KM, Li H, Xin F, Konstantinopoulos PA, Zhang R. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer. Cell Cycle 13(2):199-207, 2014. e-Pub 2014. PMID: 24200970.
- Bitler BG, Fink LS, Wei Z, Peterson JR, Zhang R. A high-content screening assay for small-molecule modulators of oncogene-induced senescence. J Biomol Screen 18(9):1054-61, 2013. e-Pub 2013. PMID: 23733845.
- Mu Z, Li H, Fernandez SV, Alpaugh KR, Zhang R, Cristofanilli M. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. J Exp Clin Cancer Res 32(1):70, 2013. e-Pub 2013. PMID: 24294976.
- Tang HY, Beer LA, Tanyi JL, Zhang R, Liu Q, Speicher DW. Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer. J Proteomics 89:165-78, 2013. e-Pub 2013. PMID: 23792823.
- Amatangelo MD, Garipov A, Li H, Conejo-Garcia JR, Speicher DW, Zhang R. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle 12(13):2113-9, 2013. e-Pub 2013. PMID: 23759589.
- Tu Z, Aird KM, Zhang R. Chromatin remodeling, BRCA1, SAHF and cellular senescence. Cell Cycle 12(11):1653-4, 2013. e-Pub 2013. PMID: 23673322.
- Tu Z, Zhuang X, Yao YG, Zhang R. BRG1 is required for formation of senescence-associated heterochromatin foci induced by oncogenic RAS or BRCA1 loss. Mol Cell Biol 33(9):1819-29, 2013. e-Pub 2013. PMID: 23438604.
- Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M, Zhang R. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep 3(4):1252-65, 2013. e-Pub 2013. PMID: 23562156.
- Garipov A, Li H, Bitler BG, Thapa RJ, Balachandran S, Zhang R. NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells. Mol Cancer Res 11(4):360-9, 2013. e-Pub 2013. PMID: 23360797.
- Aird KM, Zhang R. Detection of senescence-associated heterochromatin foci (SAHF). Methods Mol Biol 965:185-96, 2013. e-Pub 2013. PMID: 23296659.
- Li H, Zhang R. Role of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic Target. Front Oncol 3:47, 2013. e-Pub 2013. PMID: 23494175.
- Beer LA, Wang H, Tang HY, Cao Z, Chang-Wong T, Tanyi JL, Zhang R, Liu Q, Speicher DW. Identification of multiple novel protein biomarkers shed by human serous ovarian tumors into the blood of immunocompromised mice and verified in patient sera. PLoS One 8(3):e60129, 2013. e-Pub 2013. PMID: 23544127.
- Rao S, Lee SY, Gutierrez A, Perrigoue J, Thapa RJ, Tu Z, Jeffers JR, Rhodes M, Anderson S, Oravecz T, Hunger SP, Timakhov RA, Zhang R, Balachandran S, Zambetti GP, Testa JR, Look AT, Wiest DL. Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood 120(18):3764-73, 2012. e-Pub 2012. PMID: 22976955.
- Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, Hua X, Landen CN, Birrer MJ, Sánchez-Beato M, Zhang R. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol Cancer Res 10(11):1462-72, 2012. e-Pub 2012. PMID: 22964433.
- Li H, Bitler BG, Vathipadiekal V, Maradeo ME, Slifker M, Creasy CL, Tummino PJ, Cairns P, Birrer MJ, Zhang R. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila) 5(3):484-91, 2012. e-Pub 2012. PMID: 22144423.
- Tu Z, Aird KM, Zhang R. RAS, cellular senescence and transformation: the BRCA1 DNA repair pathway at the crossroads. Small GTPases 3(3):163-7, 2012. e-Pub 2012. PMID: 22751483.
- Tu Z, Aird KM, Bitler BG, Nicodemus JP, Beeharry N, Xia B, Yen TJ, Zhang R. Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence. Dev Cell 21(6):1077-91, 2011. e-Pub 2011. PMID: 22137763.
- Bitler BG, Nicodemus JP, Li H, Cai Q, Wu H, Hua X, Li T, Birrer MJ, Godwin AK, Cairns P, Zhang R. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res 71(19):6184-94, 2011. e-Pub 2011. PMID: 21816908.
- Kennedy AL, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS, McBryan T, Doyle B, McKay C, Oien KA, Enders GH, Zhang R, Sansom OJ, Adams PD. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 42(1):36-49, 2011. e-Pub 2011. PMID: 21474066.
- Li H, Cai Q, Godwin AK, Zhang R. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res 8(12):1610-8, 2010. e-Pub 2010. PMID: 21115743.
- Kennedy AL, McBryan T, Enders GH, Johnson FB, Zhang R, Adams PD. Senescent mouse cells fail to overtly regulate the HIRA histone chaperone and do not form robust Senescence Associated Heterochromatin Foci. Cell Div 5:16, 2010. e-Pub 2010. PMID: 20569479.
- Poleshko A, Einarson MB, Shalginskikh N, Zhang R, Adams PD, Skalka AM, Katz RA. Identification of a functional network of human epigenetic silencing factors. J Biol Chem 285(1):422-33, 2010. e-Pub 2010. PMID: 19880521.
- Banumathy G, Somaiah N, Zhang R, Tang Y, Hoffmann J, Andrake M, Ceulemans H, Schultz D, Marmorstein R, Adams PD. Human UBN1 is an ortholog of yeast Hpc2p and has an essential role in the HIRA/ASF1a chromatin-remodeling pathway in senescent cells. Mol Cell Biol 29(3):758-70, 2009. e-Pub 2009. PMID: 19029251.
- Poleshko A, Palagin I, Zhang R, Boimel P, Castagna C, Adams PD, Skalka AM, Katz RA. Identification of cellular proteins that maintain retroviral epigenetic silencing: evidence for an antiviral response. J Virol 82(5):2313-23, 2008. e-Pub 2008. PMID: 18094192.
- Ye X, Zerlanko B, Kennedy A, Banumathy G, Zhang R, Adams PD. Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol Cell 27(2):183-196, 2007. e-Pub 2007. PMID: 17643369.
- Ye X, Zerlanko B, Zhang R, Somaiah N, Lipinski M, Salomoni P, Adams PD. Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol 27(7):2452-65, 2007. e-Pub 2007. PMID: 17242198.
- Zhang R, Chen W, Adams PD. Molecular dissection of formation of senescence-associated heterochromatin foci. Mol Cell Biol 27(6):2343-58, 2007. e-Pub 2007. PMID: 17242207.
- Zhang R, Liu ST, Chen W, Bonner M, Pehrson J, Yen TJ, Adams PD. HP1 proteins are essential for a dynamic nuclear response that rescues the function of perturbed heterochromatin in primary human cells. Mol Cell Biol 27(3):949-62, 2007. e-Pub 2007. PMID: 17101789.
- Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM, Erzberger JP, Serebriiskii IG, Canutescu AA, Dunbrack RL, Pehrson JR, Berger JM, Kaufman PD, Adams PD. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell 8(1):19-30, 2005. e-Pub 2005. PMID: 15621527.
- Vais H, Zhang R, Reenstra WW. Dibasic phosphorylation sites in the R domain of CFTR have stimulatory and inhibitory effects on channel activation. Am J Physiol Cell Physiol 287(3):C737-45, 2004. e-Pub 2004. PMID: 15140750.
- Daganzo SM, Erzberger JP, Lam WM, Skordalakes E, Zhang R, Franco AA, Brill SJ, Adams PD, Berger JM, Kaufman PD. Structure and function of the conserved core of histone deposition protein Asf1. Curr Biol 13(24):2148-58, 2003. e-Pub 2003. PMID: 14680630.
- Zhang RG, Guo LX, Wang XW, Xie H. Telomerase inhibition and telomere loss in BEL-7404 human hepatoma cells treated with doxorubicin. World J Gastroenterol 8(5):827-31, 2002. e-Pub 2002. PMID: 12378624.
- Zhang RG, Zhang RP, Wang XW, Xie H. Effects of cisplatin on telomerase activity and telomere length in BEL-7404 human hepatoma cells. Cell Res 12(1):55-62, 2002. e-Pub 2002. PMID: 11942411.
- Zhang R, Wang X, Guo L, Xie H. Growth inhibition of BEL-7404 human hepatoma cells by expression of mutant telomerase reverse transcriptase. Int J Cancer 97(2):173-9, 2002. e-Pub 2002. PMID: 11774261.
- Zhang RG, Wang XW, Xie H. [Telomerase activity inhibition and apoptosis induction of BEL-7404 human hepatoma cells by antisense oligonucleotides to telomerase RNA component]. Shi Yan Sheng Wu Xue Bao 34(3):213-8, 2001. e-Pub 2001. PMID: 12549223.
- Wang XW, Yuan JH, Zhang RG, Guo LX, Xie Y, Xie H. Antihepatoma effect of alpha-fetoprotein antisense phosphorothioate oligodeoxyribonucleotides in vitro and in mice. World J Gastroenterol 7(3):345-51, 2001. e-Pub 2001. PMID: 11819788.
- Zhang RG, Wang XW, Yuan JH, Xie H. Human hepatoma cell telomerase activity inhibition and cell cycle modulation by its RNA component antisense oligodeoxyribonucleotides. Acta Pharmacol Sin 21(8):742-6, 2000. e-Pub 2000. PMID: 11501185.
- Yuan JH, Zhang RP, Zhang RG, Guo LX, Wang XW, Luo D, Xie Y, Xie H. Growth-inhibiting effects of taxol on human liver cancer in vitro and in nude mice. World J Gastroenterol 6(2):210-215, 2000. e-Pub 2000. PMID: 11819558.
- Zhang RG, Wang XW, Yuan JH, Guo LX, Xie H. Using a non-radioisotopic, quantitative TRAP-based method detecting telomerase activities in human hepatoma cells. Cell Res 10(1):71-7, 2000. e-Pub 2000. PMID: 10765985.
- Wang X, Zhang R, Xie H. Combined effect of alpha-fetoprotein antisense oligodeoxy-nucleotides and 5-fluorouracil on human hepatoma cell growth. Chin Med J (Engl) 112(8):743-6, 1999. e-Pub 1999. PMID: 11601286.
Other Articles
- Wang C, Hao X, Zhang R Targeting cellular senescence to combat cancer and ageing. Mol Oncol 16(18):3319-3332, 2022. PMID: 35674055.
- Hao X, Wang C, Zhang R Chromatin basis of the senescence-associated secretory phenotype. Trends Cell Biol 32(6):513-526, 2022. PMID: 35012849.
- Karakashev S, Zhang RG Mouse models of epithelial ovarian cancer for preclinical studies. Zool Res 42(2):153-160, 2021. PMID: 33527800.
- Fukumoto T, Magno E, Zhang R SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications. Mol Cancer Res 16(12):1819-1825, 2018. PMID: 30037854.
- Nacarelli T, Liu P, Zhang R Epigenetic Basis of Cellular Senescence and Its Implications in Aging. Genes (Basel) 8(12), 2017. PMID: 29186801.
- Bitler, BG, Fatkhutdinov, N, Zhang, R Potential therapeutic targets in ARID1A -mutated cancers. Expert Opinion on Therapeutic Targets 19(11):1419-1422, 2015. PMID: 26125128.
- Aird KM, Zhang R Nucleotide metabolism, oncogene-induced senescence and cancer. Cancer Lett 356(2 Pt A):204-10, 2015. PMID: 24486217.
- Aird KM, Zhang R Metabolic alterations accompanying oncogene-induced senescence. Mol Cell Oncol 1(3):e963481, 2014. PMID: 27308349.
- Zhang R, Adams PD Heterochromatin and its relationship to cell senescence and cancer therapy. Cell Cycle 6(7):784-9, 2007. PMID: 17377503.
Editorials
- Wu, S, Fatkhutdinov, N, Zhang, R. Harnessing mutual exclusivity between TP53 and ARID1 A mutations. Cell Cycle 16(24):2313-2314, 2017. PMID: 29279027.
- Zhu, H, Zhang, R. Beyond immune suppression. Translational Cancer Research 6:S102-S103, 2017.
Book Chapters
- Zhang R, Adams PD, Ye X. Design and application of a shRNA-based gene replacement retrovirus. In: Methods Mol Biol, 211-21, 2007.
- Adams PD, Zhang R, Poustovoitov MV, Seeholzer SH. Identification of associated proteins by co-immunoprecipitation. In: Protein-Protein Interactions: A Molecular Cloning Manual, 2nd edition. Cold Spring Harbor Laboratory Press.
Selected Presentations & Talks
Local Presentations
- 2024. Leveraging epigenetically driven metabolic reprogramming for developing cancer therapeutic strategies. Invited. Systems Biology Seminar Series. Houston, Texas, US.
Regional Presentations
- 2024. Leveraging epigenetic alterations to address unmet clinical needs in ovarian cancer. Invited. Reproduction Development Cancer Seminar Series. Dallas, Texas, US.
National Presentations
- 2024. Leveraging epigenetics to address unmet needs in BRCAness ovarian cancer. Invited. Center for BRCA & Related Genes Scientific Symposium. Boston, Massachusetts, US.
- 2024. Epigenetic approaches to gynecological cancers. Invited. Department of Biochemistry and Molecular Genetics Seminar Series. Birmingham, Alabama, US.
- 2024. Alumni Keynote Speaker. Invited. DoD Ovarian Cancer Academy Retreat. Seattle, Washington, US.
- 2024. Epigenetics driven metabolic vulnerabilities in ovarian cancer. Invited. Cell and Cancer Pathobiology Seminar Series. New York City, New York, US.
- 2024. Leveraging epigenetics for rational immunotherapy combination. Invited. AACR Annual Meeting. San Diego, California, US.
- 2024. Epigenetic Approaches to Gynecological Cancers. Invited. Director’s Lectureship Seminar Series. Albuquerque, New Mexico, US.
- 2023. Epigenetic approaches to endometrial cancer. Conference. AACR Special Conference in Cancer Research: Endometrial Cancer. Boston, MA, US.
- 2023. Epigenetic approaches for endometriosis-associated ovarian cancer. Conference. AACR Special Conference in Cancer Research: Ovarian Cancer. Boston, MA, US.
- 2023. RNA modifications in senescence and tissue aging. Conference. RNA Editing, Splicing, and Modification in Aging and Longevity. Bethesda, MD, US.
- 2023. Epigenetic Approaches to Epithelial Ovarian Cancer. Conference. Joint Meeting of the International Ovarian Cancer Research Consortium and The International Society of Precision Cancer Medicine. Oklahoma City, OK, US.
Formal Peers
- 2023. Overview of research interests and collaboration opportunities. Invited. Overview of research interests and collaboration opportunities. Houston, TX, US.
- 2023. Epigenetic Approaches to Gynecological Cancers. Invited. Epigenetic Approaches to Gynecological Cancers. Houston, TX, US.
- 2023. Epigenetic Approaches to Ovarian Cancer. Invited. Epigenetic Approaches to Ovarian Cancer. Columbus, OH, US.
- 2023. Epigenetic Approaches to Ovarian Cancer. Invited. Epigenetic Approaches to Ovarian Cancer. Houston, TX, US.
- 2023. Epigenetic cancer therapeutic strategies: mechanism-guided rational combinations. Invited. Epigenetic cancer therapeutic strategies: mechanism-guided rational combinations. Houston, TX, US.
- 2023. Bridging discovery and translation: from fibroblasts to ovarian cancer. Invited. Bridging discovery and translation: from fibroblasts to ovarian cancer. Houston, TX, US.
- 2023. Epigenetic Approaches to Ovarian Cancer. Invited. Epigenetic Approaches to Ovarian Cancer. Houston, TX, US.
Grant & Contract Support
| Date: | 2024 - 2029 |
| Title: | Epigenetics of Aging and Age-Associated Diseases |
| Funding Source: | University of Pennsylvania |
| Role: | Program Leader |
| ID: | P01 AG031862 |
| Date: | 2023 - 2028 |
| Title: | MDACC Ovarian SPORE – Project 4: Targeting p300 to overcome PARP inhibitor resistance induced by acidic tumor microenvironment |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2023 - 2028 |
| Title: | University of Pittsburgh Ovarian Cancer Spore – Project 2: Combination PAPRi-BETi to overcome PARPi resistance |
| Funding Source: | NIH/NCI (Pass through entity – University of Pittsburgh) |
| Role: | Co-I |
| ID: | 1 P50 CA272218-01A1 |
| Date: | 2023 - 2028 |
| Title: | Signaling Basis of Senescence-associated Secretory Phenotype and its Implications in Epithelial Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R01 CA276569-01A1 |
| Date: | 2023 - 2028 |
| Title: | Epigenetics of Aging and Age-Associated Diseases- Project 4: 3D Genomic Basis of Cellular Senescence |
| Funding Source: | NIH/NIA |
| Role: | Project Leader |
| ID: | 2-P01-AG031862-16 |
| Date: | 2023 - 2027 |
| Title: | Combined BET inhibition with ZEN3694 and PARP inhibition with talazoparib in recurrent PARPi resistant platinum-sensitive ovarian cancer |
| Funding Source: | DOD (Pass through entity – Magee-Womens Research Institute and Foundation) |
| Role: | PI |
| ID: | W81XWH-22-OCRP-CTA |
| Date: | 2023 - 2028 |
| Title: | Targeting the Epigenetic and Metabolic Control of EBV-Epithelial Cancers |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1-P01-CA269043-01A1 |
| Date: | 2023 - 2028 |
| Title: | Identification of ADAR1 Inhibitors: Promising Cancer Therapeutics and Regulators of Immunotherapy Resistance |
| Funding Source: | NIH/NIGMS |
| Role: | Co-I |
| ID: | 1-R01-GM040536-20 |
| Date: | 2023 - 2024 |
| Title: | Metabolic approaches for ARID1A-mutated ovarian cancer |
| Funding Source: | DoD OCRP (Pass through entity- The Wistar Institute) |
| Role: | Co-I |
| ID: | W81XWH-20-1-0140 (OC190181) |
| Date: | 2023 - 2028 |
| Title: | Epigenetic approaches to epithelial ovarian cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RR230005 |
| Date: | 2022 - 2026 |
| Title: | Therapeutic Targeting Mevalonate Pathway in ARID1A-Mutated Ovarian Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH-22-1-0156 |
| Date: | 2022 - 2027 |
| Title: | Metabolic Basis of ARID1A-mutated Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1-R01-CA260661-01A1 |
| Date: | 2020 - 2024 |
| Title: | Metabolic approaches for ARID1A-mutated ovarian cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | W81XWH-20-1-0140 (includes NCE) |
| Date: | 2020 - 2025 |
| Title: | Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA243511 |
| Date: | 2020 - 2022 |
| Title: | Pathway to Independence |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| Date: | 2020 - 2025 |
| Title: | Regulation of Tumor Recurrence by Stress Activated Neutrophils |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5-R01-CA243142-03 |
| Date: | 2020 - 2022 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | CA247336 |
| Date: | 2020 - 2021 |
| Title: | Ann Schreiber Mentored Investigator |
| Funding Source: | Ovarian Cancer Research Fund Alliance |
| Role: | Mentor |
| Date: | 2019 - 2022 |
| Title: | Immunological Approaches for ARID1A-mutated ovarian cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH-19-1-0154 |
| Date: | 2019 - 2023 |
| Title: | Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-A inhibitor, ipilimumab in platinum resistant ovarian cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | OC170443 |
| Date: | 2019 - 2024 |
| Title: | Synthetic Lethality Based Combination Approaches to ARID1A Mutation in Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5-R01-CA239128-04 |
| Date: | 2019 - 2024 |
| Title: | Cancer Center Support Grant |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P30 CA016672 |
| Date: | 2019 - 2020 |
| Title: | Ann Schreiber Mentored Investigator |
| Funding Source: | Ovarian Cancer Research Fund Alliance |
| Role: | Mentor |
| Date: | 2019 - 2021 |
| Title: | Developing epigenetic therapeutics for ovarian cancer |
| Funding Source: | OCRA |
| Role: | PI |
| Date: | 2018 - 2023 |
| Title: | SPORE in ovarian cancer |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | CA228991 |
| Date: | 2018 - 2023 |
| Title: | SPORE in Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | 5-P50-CA228991-04 |
| Date: | 2018 - 2023 |
| Title: | Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-A inhibitor, ipilmumab in platinum resistant ovarian cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH-18-1-0256 (NCE) |
| Date: | 2018 - 2024 |
| Title: | Epigenetics of Aging and Age-Associated Diseases- Project 4: 3D Genomic Basis of Cellular Senescence |
| Funding Source: | NIH/NIA |
| Role: | Project Leader |
| ID: | 5-P01-AG031862-15 |
| Date: | 2018 - 2019 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Mentor |
| Date: | 2018 - 2020 |
| Title: | Integration of advanced genomic and bioengineering approaches for early detection and prevention of ovarian cancer |
| Funding Source: | Tina’s Wish Foundation |
| Role: | Co-PI |
| Date: | 2016 - 2019 |
| Title: | Synthetic lethal therapeutic approaches for ARID1A-mutated ovarian cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | OC150446 |
| Date: | 2016 - 2017 |
| Title: | Ann Schreiber Mentored Investigator |
| Funding Source: | Ovarian Cancer Research Fund |
| Role: | Mentor |
| Date: | 2015 - 2026 |
| Title: | Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5-R01-CA202919-07 |
| Date: | 2015 - 2017 |
| Title: | Pathway to Independence |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| Date: | 2015 - 2018 |
| Title: | Therapeutic strategies against cyclin E1 amplified ovarian cancers |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | OC140632P1 |
| Date: | 2015 - 2017 |
| Title: | Pathway to Independence |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| Date: | 2015 - 2018 |
| Title: | The Jayne Koskinas Ted Giovanis Breast Cancer Research Consortium |
| Funding Source: | The Jayne Koskinas and Ted Giovanis Foundation |
| Role: | Investigator |
| Date: | 2015 - 2017 |
| Title: | Program Development project 3: Microenvironmental control of premalignant lesions in ovarian cancer |
| Funding Source: | Ovarian Cancer Research Fund |
| Role: | Project Leader |
| Date: | 2014 - 2016 |
| Title: | PARP inhibitor resistance and overcoming strategies in ovarian cancer |
| Funding Source: | Penn Basser BRCA Center |
| Role: | Co-I |
| ID: | Team Science Award |
| Date: | 2014 - 2016 |
| Title: | Development of senescence-based novel melanoma therapeutic strategies |
| Funding Source: | NIH/NCI |
| Role: | PI Pilot Project |
| Date: | 2014 - 2019 |
| Title: | Identification of ovarian cancer plasma biomarkers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | CA131582 |
| Date: | 2014 - 2017 |
| Title: | Program Development project 1: Chromatin regulatory mechanisms in ovarian cancer |
| Funding Source: | Ovarian Cancer Research Fund |
| Role: | Project Leader |
| Date: | 2013 - 2015 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Mentor |
| Date: | 2012 - 2023 |
| Title: | Targeting EZH2 in CARM1-expressing Epithelial Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5-R01-CA163377-10 (NCE) |
| Date: | 2012 - 2023 |
| Title: | Chromatin Basis of Cellular Senescence and its Implication in Epithelial Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5-R01-CA160331-10 (NCE) |
| Date: | 2010 - 2015 |
| Title: | Determine the Role of Canonical Wnt Signaling in Ovarian Tumorigenesis |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | OC093420 |
| Date: | 2009 - 2012 |
| Title: | Targeting BRCA1/2 deficiency in ovarian cancer |
| Funding Source: | NIH/NCI |
| Role: | Investigator |
| ID: | FCCC-UPenn Ovarian SPORE |
| Date: | 2009 - 2012 |
| Title: | Oncogene-Induced Senescence Suppresses Ovarian Carcinogenesis |
| Funding Source: | Ovarian Cancer Research Fund |
| Role: | PI |
| ID: | Liz Tilberis Scholar |
| Date: | 2009 - 2012 |
| Title: | Program project 2 development: Therapeutic Targeting of the Tumor Microenvironment in Ovarian Cancer |
| Funding Source: | Ovarian Cancer Research Fund |
| Role: | Project Leader |
| ID: | PPD/FCCC/01.09 |
Patient Reviews
CV information above last modified March 27, 2025